Changes in plasma sclerostin level associated with use of a medium cut-off dialyzer in end-stage renal disease.
- Greater reduction ratio in MCO than in control for several larger middle molecules: growth differentiation factor 15 (GDF15) 62.6% vs 35.7% (p<0.001); sclerostin 52.6% vs 31.6% (p < 0.001); FGF23 47.8% vs 18.9% (p = 0.005); RBP4 24.4% vs 7.2% (p = 0.005). Significant difference between the two groups in change of plasma sclerostin over 12 months (adjusted mean difference: -1,647 pg/ml, p = 0.021).